Angiogenesis in Wound Healing following Pharmacological and Toxicological Exposures

Hunter, Russell; Kivlighan, Katie T.; Ruyak, Sharon L.; Jacquez, Quiteria; Zychowski, Katherine E.

doi:10.1007/s40139-020-00212-y

Cited by 3 publications

(2 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, vascular endothelial growth factor has a signi cant impact on the wound healing cascade, in uencing various stages of this process, including hemostasis, the in ammatory phase, the proliferation phase, and the maturation phase 22 . In other words, throughout the healing process, which could also explain our observation of delayed healing.…”

Section: Discussionmentioning

confidence: 99%

The impact of Bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria

BOUDJELAL,

MELZI,

BOUAMRA

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives: Bevacizumab currently stands as the most prescribed anti-VEGF medication in oncology. It functions as an angiogenesis inhibitor, thereby slowing down tumor progression. However, this drug is associated with side effects both in general health and in the oral cavity. To assess the impact of Bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria. Materials and Methods: We conducted a cohort study that was comparative, prospective, and multicentric, carried out from June 2018 to September 2021. The sample was divided into two groups: the "With Bevacizumab" group consisted of patients on Bevacizumab with or without chemotherapy, and the second group "Without Bevacizumab" consisted of patients exclusively under conventional chemotherapy. These patients underwent dental extractions without interrupting their antineoplastic treatment. Additionally, the dental extraction protocol adhered to certain conditions, including antibiotic prophylaxis, vasoconstrictor-free anesthetic, and tight sutures. Mucosal healing was evaluated and monitored at 7, 15, and 30 days. Data analysis was performed using Python v. 3.8.16 software. Results: In total, 1250 cancer-treated patients were examined. Among them, 120 patients met the inclusion criteria, with a mean age of 52.08 ± 10.31 years, and they received an average dose of 547.9 ± 239.32 mg of Bevacizumab per cycle over an average duration of 40.08 ± 31.66 weeks. The mean total duration of treatment-free interval with Bevacizumab was estimated at 23.13 ± 7.03 days, with 12.85 ± 5.58 days before and 10.28 ± 4.68 days after dental extraction. Mucosal healing delay was only observed in the "With Bevacizumab" group (15.3% vs. 0.0%, p=0.040). Conclusions: Dental extraction is feasible during Bevacizumab treatment considering the disadvantages associated with interrupting anti-angiogenic treatment, despite the observed delay in epithelialization in our study. Clinical Relevance: Our results were able to demonstrate delayed mucosal healing (lack of epithelialization) beyond one month after tooth extraction.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of Bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria

BOUDJELAL,

MELZI,

BOUAMRA

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Nrf2 has also been demonstrated to activate in response to tissue damage and may collaborate with other transcription factors to speed up the healing process [35][36][37][38]. Transcriptional regulators are important players in diabetic wound healing, activating or inhibiting gene expression in complex cellular and molecular process at different stages of wound healing [44]. The signal transducer and activator of transcription 3 are key players in keratinocyte proliferation and differentiation at the wound site signal transducer and activator of transcription 3 (STAT3).…”

Section: Role Of Nrf2 In Diabetic Wound Healingmentioning

confidence: 99%

Nrf2 Mediated Heme Oxygenase-1 Activation Contributes to Diabetic Wound Healing – an Overview

et al. 2022

View full text Add to dashboard Cite

Diabetic wound healing is a complicated procedure because hyperglycemia changes the various stages of wound healing. In type 2 diabetes mellitus (T2DM), oxidative stress is proven to be a critical factor in causing non-healing wounds and aggravating the inflammatory phase, resulting in the amputation of lower limbs in T2DM patients. This makes scientists figure out how to control oxidative stress and chronic inflammation at the molecular level. Nuclear factor erythroid 2- related factor 2 (Nrf2) releases antioxidant proteins to suppress reactive oxygen species (ROS) activation and inflammation. The current review discusses the role of Nrf2 in improving diabetic wound healing by reducing the production of ROS and thus reducing oxidative stress, as well as inhibiting nuclear factor kappa B (NF-kB) dissociation and nuclear translocation, which prevents the release of inflammatory mediators and increases antioxidant protein levels, thereby improving diabetic wound healing. As a result, the researcher will be able to find a more effective diabetic wound healing therapy.

show abstract

Drug eluting titanium implants for localised drug delivery

Singh

Gill

Deol³

et al. 2022

Journal of Materials Research

View full text Add to dashboard Cite

Angiogenesis in Wound Healing following Pharmacological and Toxicological Exposures

Cited by 3 publications

References 125 publications

The impact of Bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria

The impact of Bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria

Nrf2 Mediated Heme Oxygenase-1 Activation Contributes to Diabetic Wound Healing – an Overview

Drug eluting titanium implants for localised drug delivery

Contact Info

Product

Resources

About